Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 20071 |
Prequalification programme:Priority essential medicinesPrequalification programme:Priority essential medicines
Training programme on pharmaceutical quality, good
manufacture practice and bioequivalence with a focus on TB
products.
Jiaxing
Peoples’ Republic of China
5 – 9 November 2007
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 20072 |
Training Workshop on Evaluation of quality and interchangeability of medicinal products.
Training Workshop on Evaluation of quality and interchangeability of medicinal products.
ANALYTICAL VALIDATION
Presenter: Drs. J. Welink
Senior pharmacokineticist
Medicines Evaluation Board, NL
WHO adviser
E-mail: [email protected]
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 20073 |
HistoryHistory
Development pharmacokinetics:
computers
separation technics
analytical methods
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 20074 |
HistoryHistory
chromatography
spectrometry
gas chromatrography
liquid chromatography
mass spectrometry
'30
‘50
‘60
‘70
‘90
mg/ml
μg/ml
ng/ml
pg/ml
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 20075 |
MethodsMethods
ANALYTICAL METHODS
immunological methods
LC-MS/MS
GLCHPLC
GC-MS
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 20076 |
PrinciplePrinciple
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 20077 |
GuidanceGuidance
FDA Guidance for Industry– Bioanalytical method validation, May 2001
ICH Guidance for industry– Validation of analytical methods: definitions and
terminology, June 1995 – Validation of analytical procedures: methodology,
November 1996
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 20078 |
GCP/GLPGCP/GLP
GCP/GLP compliance– Clinical studies have to be performed under
conditions complying with the principles of Good Clinical Practice, and for analytical methods and sample data handling conditions complying with the principles of Good Laboratory Practice are required.
– For older studies without statement of complinace with the above mentioned principles, the assessor should rely on the quality of the submitted report.
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 20079 |
Choices of methodsChoices of methods
LC-MS-MS
GC-MS
HPLC
GLC
Immunological methods
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200710 |
Choices of methodsChoices of methods
Method used for the determination of drugs and/or metabolites should be:
SensitiveAccurateDiscriminativePrecise
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200711 |
SensitivitySensitivity
Method should be able to quantify the drug in the sampled specimen at least 10 % of the maximum concentration reached after dosing.
Limit of Quantification (LOQ): 1/10 Cmax
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200712 |
DiscriminativeDiscriminative
The method should be able to discriminate between the selected analyte and interfering compounds from the environment or from other compounds administered simultaneously
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200713 |
AccuracyAccuracy
The method must be accurate enough to measure the true value (concentration) of the analyte in a relative small sample
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200714 |
PrecisionPrecision
The analytical method should be presice enough to reveal identical results when the procedure is applied repeatedly to multiple aliquots of a single homogeneous volume of the biological matrix
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200715 |
ValidationValidation
To measure is to know!
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200716 |
ValidationValidation
Specificity
Detection limit (LOD)
Quantification limit (LOQ)
Linearity
Range
Accuracy
Precision
Robustness
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200717 |
Validation-specificityValidation-specificity
Investigation of specificity should be conducted during the validation phase of the assay
The procedures used to demonstrate specificity should be clearly reported
Must be applied with structurally similar materials
Choices base on scientific judgements
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200718 |
Validation-specificityValidation-specificity
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200719 |
Validation-LODValidation-LOD
Various methods possible
visual evaluation• minimum level at which the analyte can be
detected reliably
signal-to noise• 3:1 ratio is acceptable
standard deviation of the slope and response• LOD = 3.3 σ / S
– σ = standard deviation of the response– S = slope of the calibration curve
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200720 |
Validation-LOQValidation-LOQ
Based on signal-to noise– Reliable quantification is a 10:1 ratio
Based on SD of the response and the slope – LOQ = 10 σ / S
• σ = standard deviation of the response• S = slope of the calibration curve
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200721 |
Validation-LOD/LOQValidation-LOD/LOQ
Recommended data:
The LOD and LOQ and the method used for the LOQ should be presented
The limits should be validated by the analyses of a suitable number of samples prepared at the LOD and LOQ limits
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200722 |
Validation-LODValidation-LOD
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200723 |
LOQ, LOD and SNR
Limit of Quantitation
Limit of Detection
Signal to Noise Ratio
noise
Peak ALOD
Peak BLOQ
Baseline
Validation
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200724 |
Validation-linearityValidation-linearity
Should be evaluated across the range of concentrations expected during the study
A minimum of five concentrations used in the range is recommended
The correlation coefficient, y-intercept slope of the regression and residual sum of squares should be submitted
Deviations from the regression line should be analysed for evaluating linearity
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200725 |
Validation-linearityValidation-linearity
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200726 |
Validation-rangeValidation-range
The specified range is derived from linearity studies and should cover the extremes of the concentrations probably reached during the study
The range should be justified in the report based on scientific information
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200727 |
Validation-accuracyValidation-accuracy
Accuracy should be assessed on samples spiked with known amounts of the analyte
Accuracy should be assessed using determinations over a minimum of 3 concentration levels (low, medium and high)
Accuracy should be reported as percent recovery from the added amount and with confidence intervals
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200728 |
Validation-accuracyValidation-accuracy
LQC
MQC
HQC
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200729 |
Validation-precisionValidation-precision
Repeatability– concentrations covering the specified range
Intermediate precision– Like days, analysts, equipment
Reproducibility– Determined if analyses take place in separate periods
Recommended data– SD, Coefficient of variations, and confidence intervals
should be reported on each type of precision
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200730 |
Validation-accuracy/precisionValidation-accuracy/precision
Accuracy/precision:
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200731 |
Validation-accuracy/precisionValidation-accuracy/precision
Intra-day:Between-day:
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200732 |
Validation-accuracy/precision:Validation-accuracy/precision:
Accuracy/precision calibrators:
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200733 |
Validation-accuracy/precisionValidation-accuracy/precision
FDA
Accuracy
within-run between-run
normally: <15%
LLOQ: <20%
Precision
within-run between-run
normally: <15%
LLOQ: <20%
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200734 |
Validation-robustnessValidation-robustness
Robustness should be considered during development phase
Shows the reliability of the analytical method with respect to variations in the method parameters
In case variations occur they should be suitably controlled and if present adequately tested and documented
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200735 |
Validation-robustnessValidation-robustness
Typical examples:
Stability of the analytical solutions– Influence of variations of pH of the mobile phase– Influence of variations of mobile phase
composition– Influence of temperature and flow rate
Extraction conditions– pH and extraction time
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200736 |
Validation-robustnessValidation-robustness
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200737 |
Validation-recoveryValidation-recovery
Recovery:
Extraction efficiency analytical method– consistent– precise– reproducible
Recovery:80%75%91%97%65%73%
mean: 81.1%
CV: 14.7%
Recovery:15%16%13%15%16%14%
mean: 14.8%
CV: 7.9%
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200738 |
Validation-stabilityValidation-stability
Required data – Freeze and thaw stability– Short term temperature stability– Long term stability– Stock solution stability– Post preparation stability
Stability assessed prior sample analysis!
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200739 |
Analysis clinical samplesAnalysis clinical samples
The analytical method should be validated before the start of obtaining clinical samples.
Each analytical run should contain sufficient QC samples at the beginning, middle and end at at least 3 levels (LQC, MQC and HQC).
QC QCQC QC QCQC
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200740 |
Analysis clinical samplesAnalysis clinical samples
Acceptation or rejection of a run should be predefined before the actual start of the analysis of the clinical samples.
QC QCQC QC QCQC
FDA criteria
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200741 |
Analysis clinical samplesAnalysis clinical samples
All samples of 1 subject in 1 run
Subject sample reanalysis should be predefined before the actual start of the analysis of the clinical samples.
QC QCQC QC QCQC
Reasons: -improper sample injection
-mailfunction -concentration > HLOQC
-unexpected value -PK reason
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200742 |
Analysis clinical samplesAnalysis clinical samples
-unexpected value
-PK reason
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200743 |
ReportReport
All methods should be covered by adequate Standard Operating Procedures (SOP’s) for general and analysis specific procedures
Before the start of an analytical procedure an adequate study plan has to be written or be incorporated in the study protocol
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200744 |
ReportReport
A specific detailed description of the bioanalytical method should be written
All experiments used to make claims or draw conclusions should be presented in the report
GLP compliance/inspections/audits
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200745 |
ReportReport
The following data are required on the report:1) Author(s) and their affiliation2) Name of the institute or company where the
investigations have been performed.3) Date of publication analytical study
4) Identification number of the report.
N.B. The report should preferably be printed on original marked paper of the applicant or of the institute where the analysis has been performed.
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200746 |
ReportReport
* For which compounds are the samples analysed (active substance, active and/or quantitatively important metabolite)
* Sample pre-treatment and extraction.
* Analytical method is used.
* Source of the analytical method
- references from literature
- modifications in the procedure.
* Validation of the analytical method
- minimal detectable concentration, stability, reproducibility
- linearity, precision, accuracy, selectivity, sensitivity
- inter- and intraday variability
All individual measurements have to be presented in the report!
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200747 |
ReportReport
Analysis of subject samples in a separate report
* Reference to validation report
* Handling samples
* Set up analytical run
* Within study validation results
* Re-analysis
* Chromatograms
* Identification results
All individual measurements have to be presented in the report!
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200748 |
ExampleExample
Accuracy/precision:
normally: <15%
LLOQ: <20%
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November 200749 |
EndEnd
Be organised!